Skip to main content
ACU
NYSE Manufacturing

Acme United Q3 Sales Jump 18% to $58.0M; Tariff Refund Lifts Gross Margin to 45.3%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Positive
Importance info
7
Price
$70.28
Mkt Cap
$269.441M
52W Low
$35.5
52W High
$72.207
52W Position info
98% above low
Off High info
2.7% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ACU sits 98% above its 52-week low of $35.5.

Summary

Acme United grew Q3 sales 18% to $58.0 million and net income to $3.4 million, but a one-time $4.0 million tariff refund drove most of the gross-margin gain while debt rose to fund the My Medic acquisition and inventory.


Key Events · Earnings and Guidance · ACU

  • Q3 Sales Up 18% to $58.0M

    Net sales were $58,013K versus $49,063K a year ago; excluding the My Medic acquisition, sales rose 10%. Nine-month sales were $173,030K, up 16%.

  • Tariff Refund Inflates Gross Margin

    Gross profit was $26,300K (45.3% of sales) versus $19,195K (39.1%). A $4.0M IEEPA tariff refund added 690 bps, partly offset by $1.8M of DMT facility closing costs (-310 bps).

  • Net Income $3.4M, Diluted EPS $0.80

    Q3 net income rose to $3,435K from $1,903K; diluted EPS $0.80 versus $0.46. Nine-month net income was $9,469K ($2.29 diluted).

  • Debt Rises to Fund Acquisition

    Revolver borrowings increased $16.2M to $28,453,036, with $36,546,964 available under the new $65M facility maturing July 15, 2029. Long-term debt to equity rose to 29.8% from 18.1%.


Analysis · ACU · Manufacturing

Acme United's third quarter shows real top-line momentum: sales rose 18% to $58.0 million, and even excluding the My Medic acquisition they were up 10%. The headline margin gain, however, is flattered by a one-time $4.0 million IEEPA tariff refund that added 690 basis points to gross margin, partly offset by $1.8 million of costs to close the DMT plant. Strip those out and the underlying business still grew, but the quality of the beat is mixed. Net income of $3.4 million ($0.80 diluted) versus $1.9 million a year ago reflects the refund more than operating leverage. Balance sheet leverage is the thing to track: revolver borrowings rose $16.2 million to $28.5 million to fund the My Medic deal and inventory build, pushing long-term debt to equity to 29.8% from 18.1%. Management says cash flow plus the new $65 million facility covers the next twelve months.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACU was trading at $70.28 on NYSE in the Manufacturing sector, with a market capitalization of approximately $269.4M. The 52-week trading range was $35.50 to $72.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACU - Latest Insights